Action KURA KURA ONCOLOGY, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Kura Oncology, Inc.

Actions

KURA

US50127T1097

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 06/06/2024 		Varia. 5j. Varia. 1 janv.
22,06 USD +1,24 % Graphique intraday de Kura Oncology, Inc. +6,62 % +53,41 %
24/05 Kura Oncology, Inc. Complète le recrutement de 85 patients dans la portion phase 2 de KOMET-001 CI
15/05 Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Kura Oncology to Participate in Jefferies Global Healthcare Conference
Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology : Corporate Presentation - May 2024
Kura Oncology: Q1 Earnings Snapshot
Kura Oncology Reports First Quarter 2024 Financial Results
Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kura Oncology to Report First Quarter 2024 Financial Results
Sector Update: Health Care Stocks Advance Premarket Monday
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KURA
  4. Actualités Kura Oncology, Inc.
  5. Autres langues